Search

Your search keyword '"Valk, Peter"' showing total 46 results
Start Over Author "Valk, Peter" Topic positron emission tomography
46 results on '"Valk, Peter"'

3. Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-hodgkin's lymphoma patients

Author

Filmont, Jean-Emmanuel, Vranjesevic, Duska, Quon, Andrew, Margolis, Daniel J.A., Ko, Fred, Safaei, Arash, Emmanouilides, Christos, Silverman, Daniel H.S., Rao, Jyotsna, Valk, Peter E., Phelps, Michael E., and Czernin, Johannes

Subjects
LYMPHOMAS, POSITRON emission tomography, RETICULOENDOTHELIAL granulomas, MEDICAL imaging systems, MEDICAL equipment
Abstract

PURPOSE: The aim of this study was to determine the impact of positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) and combined conventional imaging on clinical stage and their ability to predict the clinical outcome of previously treated lymphoma patients.PROCEDURES: Seventy-eight patients with Non-Hodgkin''s Lymphoma (NHL) were studied with PET within a median interval of 5.3 months after treatment. Conventional imaging performed after treatment and within three months before PET included 3.3±1.3 imaging tests/patient. To determine the independent ability of PET for predicting clinical outcome, PET images were re-read in a blinded fashion. Study endpoints were disease-free survival, or clinical evidence of disease or death.RESULTS: PET downstaged 18 patients, upstaged nine and revealed the same stage as conventional imaging in 51 patients. Using the clinical outcome as gold standard, the positive and negative predictive values of PET were 95% and 83% versus 72% and 67% for conventional imaging (P<0.05). The prognostic accuracy of PET was superior to that of conventional imaging (90 vs. 71%; P<0.05). Kaplan-Meier analysis for disease-free survival showed a significant difference between PET negative and PET positive results (P<0.0001).CONCLUSION: Whole-body FDG-PET imaging modified the clinical stage in 35% of lymphoma patients who were reevaluated after treatment. Moreover, FDG-PET predicted patient outcome with a higher predictive accuracy than conventional imaging. This superior prognostic accuracy was achieved with a single FDG-PET study versus multiple conventional imaging procedures/patient. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

4. The Impact of 2-Deoxy-2[18F] Fluoro-D-Glucose Whole Body Positron Emission Tomography for Managing Patients with Melanoma: The Referring Physician's Perspective

Author

Wong, Catharina, Silverman, Daniel H., Seltzer, Marc, Schiepers, Christiaan, Ariannejad, Maryam, S.Gambhir, Sanjiv, Phelps, Michael E., Rao, Jyotsna, Valk, Peter, and Czernin, Johannes

Subjects
POSITRON emission tomography, MELANOMA, PATIENTS
Abstract

Purpose: Whole body positron emission tomography (PET) imaging with 2-deoxy-2[18F]fluoro-D-glucose (FDG) has been used successfully to diagnose and stage melanoma. The impact of FDG-PET, however, on patient stage and management from the referring physicians'' perspective is unknown.Procedures: A questionnaire was sent to referring physicians to investigate whether and how PET altered clinical decision in treatment of melanoma patients. Surveys were sent to referring physicians of every melanoma patient who had a PET scan performed at UCLA or the Northern California PET Imaging Center (NCPIC). Data were used to evaluate the impact of FDG-PET on clinical management of melanoma patients based on pre-PET and post-PET staging. Management changes were classified as inter-modality if therapy changed from one modality to another or intra-modality if changes were made within a treatment modality.Results: Fifty-one questionnaires (response rate of 35%) have been received to date. Referring physicians indicated that whole body FDG-PET changed the clinical stage in 15 out of 51 (29%) patients: 10 (20%) were up-staged and five (10%) were down-staged. The PET findings resulted in inter-modality management changes in 15 out of 51 patients (29%). Intra-modality management change occurred in nine patients (18%).Conclusion: From the referring physicians'' perspective, FDG-PET has a major impact and results in management changes in 53% of patients with melanoma. (Mol Imag Biol 2002;4:185–190) [Copyright &y& Elsevier]

Published
2002
Full Text
View/download PDF

5. [sup 18]F]Fluorodeoxyglucose in Management of Recurrent Colorectal Cancer.

Author

Valk, Peter E., Abella-Columna, Elma, Haseman, Michael K., Pounds, Thomas R., Tesar, Ruth D., Myers, Richard W., Greiss, Hani B., and Hofer, Glenn A.

Subjects
POSITRON emission tomography, COLON cancer
Abstract

Hypothesis: Metabolic imaging by positron emission tomography (PET) using [[sup 18]F]fluorodeoxyglucose will be more accurate than anatomic imaging by computed tomography (CT) for detection of recurrent colorectal cancer. More accurate staging of recurrent tumor by PET will lead to more appropriate management decisions. Design: Prospective blinded study comparing PET with CT, using histologic diagnosis, serial CT imaging, and clinical follow-up as criterion standards, with a fully blinded, retrospective reinterpretation of PET studies. Changes in diagnosis resulting from PET findings were correlated with subsequent treatment and surgical findings. Potential cost savings resulting from use of PET for preoperative staging were calculated. Setting: Private practice in an outpatient tertiary referral center. Patients: A group of 155 consecutive patients with imaging for diagnosis or staging of recurrent colorectal cancer. Twenty-one patient (14%) were excluded due to lack of a criterion standard. Computed tomographic scans were available for comparison for 115 patients. Results: Positron emission tomographic scan sensitivity and specificity were 93% and 98%, respectively, compared with 69% and 96% for CT. Ninety-five percent confidence intervals for the differences between the modalities were 16% to 32% for sensitivity and 1% to 5% for specificity. The sensitivity of both modalities varied with anatomic site of recurrence. Positron emission tomographic scans were true positive in 12 (67%) of 18 patients with elevated serum carcinoembryonic antigen levels and negative CT findings. In 23 (29%) of 78 preoperative studies in which CT showed a single site of recurrence, PET showed tumor at additional sites. At surgery, nonresectable, PET-negative tumor was found in 7 (17%) of 42 patients who had PET evidence of localized recurrence only. Potential savings resulting from demonstration of nonresectable tumor by PET were calculated at $3003 per preoperative study. Con... [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

6. PET and PET/CT Imaging in Lymphoma

Author

Jerusalem, Guy H. M., Hustinx, Roland, Rigo, Pierre, Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

8. PET and PET/CT Imaging in Lung Cancer

Author

Rigo, Pierre, Hustinx, Roland, Bury, Thierry, Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

10. The Technologist’s Perspective

Author

Cronin, Bernadette F., Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

12. PET Imaging in Brain Tumors

Author

Wong, Terence Z., Coleman, R. Edward, Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

14. PET in Clinical Neurology

Author

Tai, Yen F., Piccini, Paola, Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

15. PET in Clinical Cardiology

Author

Bengel, Frank M., Schwaiger, Markus, Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

20. PET Imaging in Pediatric Disorders

Author

Jadvar, Hossein, Connolly, Leonard P., Fahey, Frederic H., Shulkin, Barry L., Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

21. PET Imaging of the Skeleton

Author

Cook, Gary J. R., Fogelman, Ignac, Israel, Ora, Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

22. Basic Science of PET and PET/CT

Author

Townsend, David W., Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

25. PET and PET/CT in Sarcoma

Author

O’Doherty, Michael J., Smith, Michael A., Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

30. PET and PET/CT Imaging in Melanoma

Author

Segall, George M., Swetter, Susan M., Valk, Peter E., editor, Delbeke, Dominique, editor, Bailey, Dale L., editor, Townsend, David W., editor, and Maisey, Michael N., editor

Published
2006
Full Text
View/download PDF

45. Malignant Melanoma

Author

Risse, J. H., Palmedo, H., Bender, H., Bender, Hans, editor, Palmedo, Holger, editor, Biersack, Hans-Jürgen, editor, and Valk, Peter E., editor

Published
2000
Full Text
View/download PDF

46. Introduction

Author

Biersack, H.-J., Bender, Hans, editor, Palmedo, Holger, editor, Biersack, Hans-Jürgen, editor, and Valk, Peter E., editor

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results